Save up -80% on Ledipasvir
Note: this is a drug discount program, not an insurance plan.
2018 Price of Ledipasvir
* price without discount in nearest pharmacy. Price may vary.
We offer free Ledipasvir coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Ledipasvir every time. What are you waiting for? Claim your prescription drug card now!
Ledipasvir volume of distribution
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Ledipasvir
Ledipasvir, previously known as GS-5885, is an inhibitor of the Hepatitis C Virus (HCV) NS5A protein required for viral RNA replication and assembly of HCV virions. Although its exact mechanism of action is unknown, it is postulated to prevent hyperphosphorylation of NS5A which is required for viral production. It is effective against genotypes 1a, 1b, 4a, and 5a and with a lesser activity against genotypes 2a and 3a of HCV. Ledipasvir is available as a fixed dose drug combination product with sofosbuvir (tradename Harvoni) used for the treatment of chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Approved in October 2014 by the FDA, ledipasvir and sofosbuvir are direct-acting antiviral agents indicated for the treatment of HCV genotype 1 with or without cirrhosis. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States affecting 72% of all chronic HCV patients. Prior to development of this drug, the main treatment available was weekly injections of pegylated interferon with weight-based ribavirin over 48 weeks, which achieved a sustained virological response (SVR) of 45-50% and had multiple unpleasant side effects. When combined together, ledipasvir and sofosbuvir have been shown to have a SVR between 93 and 100% after 12 weeks of treatment. Its use has also proven successful in the treatment of HCV in patients co-infected with HIV.
Ledipasvir mechanism of action
Ledipasvir is an inhibitor of the Hepatitis C Virus (HCV) NS5A protein required for viral RNA replication and assembly of HCV virions. Although its exact mechanism of action is unknown, it is postulated to prevent hyperphosphorylation of NS5A which is required for viral production. It is effective against genotypes 1a, 1b, 4a, and 5a and with a lesser activity against genotypes 2a and 3a of HCV.
Dosage forms of Ledipasvir
|Tablet, film coated||oral|
Gilead Sciences Canada Inc
Indication of Ledipasvir
Ledipasvir in combination with sofosbuvir, or in combination with sofosbuvir and ribavirin, is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.
Toxicity of Ledipasvir
There is very little toxicity associated with the use of ledipasvir in combination products. The most common adverse reactions are headache and fatigue.
RX24 Drugs Disclaimer: before buying a Ledipasvir on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.